Trial Profile
MB001-067 A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO (COHORT A) AND A PROSPECTIVE, SINGLE GROUP, OPEN-LABEL, BLINDED OUTCOME TRIAL OF EXTENDED RELEASE EXENATIDE (COHORT B) IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS TRIAL) AMENDMENT 3
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.
- 13 Jul 2020 Planned End Date changed from 1 Mar 2020 to 1 Nov 2020.
- 13 Jul 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Nov 2020.